- Home
- CHRS vs MRCC Comparison
CHRS vs MRCC Comparison
Compare CHRS & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- MRCC
- Stock Information
- Founded
- CHRS 2010
- MRCC 2011
- Country
- CHRS United States
- MRCC United States
- Employees
- CHRS N/A
- MRCC N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- MRCC Investment Managers
- Sector
- CHRS Health Care
- MRCC Finance
- Exchange
- CHRS Nasdaq
- MRCC Nasdaq
- Market Cap
- CHRS 159.2M
- MRCC 155.1M
- IPO Year
- CHRS 2014
- MRCC 2012
- Fundamental
- Price
- CHRS $1.35
- MRCC $7.56
- Analyst Decision
- CHRS Strong Buy
- MRCC Hold
- Analyst Count
- CHRS 4
- MRCC 1
- Target Price
- CHRS $4.51
- MRCC $8.00
- AVG Volume (30 Days)
- CHRS 1.2M
- MRCC 73.5K
- Earning Date
- CHRS 11-05-2025
- MRCC 11-11-2025
- Dividend Yield
- CHRS N/A
- MRCC 13.12%
- EPS Growth
- CHRS N/A
- MRCC N/A
- EPS
- CHRS 1.55
- MRCC 0.09
- Revenue
- CHRS $272,209,000.00
- MRCC $51,229,000.00
- Revenue This Year
- CHRS N/A
- MRCC N/A
- Revenue Next Year
- CHRS $109.48
- MRCC N/A
- P/E Ratio
- CHRS $0.87
- MRCC $86.31
- Revenue Growth
- CHRS 52.33
- MRCC N/A
- 52 Week Low
- CHRS $0.66
- MRCC $5.96
- 52 Week High
- CHRS $2.43
- MRCC $8.85
- Technical
- Relative Strength Index (RSI)
- CHRS 64.99
- MRCC 71.70
- Support Level
- CHRS $1.23
- MRCC $7.41
- Resistance Level
- CHRS $1.40
- MRCC $7.65
- Average True Range (ATR)
- CHRS 0.08
- MRCC 0.12
- MACD
- CHRS -0.00
- MRCC -0.03
- Stochastic Oscillator
- CHRS 72.13
- MRCC 62.96
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.